Expert Analysis

Management of Treatment-Experienced Patients

Source: CCO Independent Conference Coverage of the 2008 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Management of Treatment-Experienced Patients

Faculty:

Joseph J. Eron, Jr., MD
W. David Hardy, MD
Kimberly Y. Smith, MD, MPH

CME CREDIT INFORMATION

Release Date: 03/24/08

Expiration Date: 03/23/09

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing CE credits

Pharmacists: 1.5 contact hours (0.15 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount the results of the BENCHMRK, DUET, and MOTIVATE trials of newly approved agents for treatment-experienced patients
Discuss the new analysis of data from the SMART study of antiretroviral treatment interruption in HIV-infected patients
Describe the results of a trial of therapeutic drug monitoring to guide dosages of drugs for patients with drug-resistant virus

Topics covered include:

Updated Data on the Use of CCR5 Antagonists—Maraviroc and Vicriviroc—in Treatment-Experienced Patients
48-Week Data From BENCHMRK 1 and 2 on the Use of Raltegravir Plus OBR in Triple Class–Resistant Patients
48-Week Data From DUET-1 and -2 on the Use of Etravirine Plus OBR in Treatment-Experienced Patients
Dose Escalation of PIs in Patients With Normalized Inhibitory Quotient ≤ 1
The SMART Study: Impact of Previous Intermittent Treatment on Clinical Outcomes After an 18-Month Follow-up
Incidence of Failure on Second HAART Regimen
Impact of Delayed Regimen Modification in Patients Failing First-Line NNRTI-Based Treatment
Use of Darunavir in HIV-Infected, Treatment-Experienced Children
New Agents in Development for Treatment-Experienced Patients

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.